SCHEMBL249553

SCHEMBL249553

CCCCCCCCCCCCCCC(CC)C(=O)O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.83
MAPK1 P28482 1/20 0.83
GRIK1 P39086 2/20 0.63
GRIK2 Q13002 2/20 0.63
SLC1A2 P43004 2/20 0.60
SLC1A1 P43005 2/20 0.60
GPR84 Q9NQS5 5/20 0.59
FFAR1 O14842 1/20 0.59
MAPT P10636 1/20 0.57
LCK P06239 1/20 0.57
PPARD Q03181 1/20 0.57
ZDHHC20 Q5W0Z9 1/20 0.57
ZDHHC2 Q9UIJ5 1/20 0.57
CA1 P00915 1/20 0.54
ACE2 Q9BYF1 1/20 0.53
CHRM1 P11229 1/20 0.52
AKR1A1 P14550 1/20 0.52
CHRM3 P20309 1/20 0.52
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167273 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL10788879 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL687840 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL1704587 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
Hexane SCHEMBL4788148 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL2492860 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL17329112 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
Hexane SCHEMBL18237384 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL3003696 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL1645242 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025108545-A1 DELIVERY OF NUCLEOTIDES FROM INJECTABLE BIOMATERIAL DANMARKS TEKNISKE UNIVERSITET (DK) 2025-05-30 WO claimed
EP-4529477-A1 POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS Danmarks Tekniske Universitet (DK) 2025-04-02 EP claimed
EP-3512351-B1 COMPOSITIONS AND METHODS FOR IMPROVING TASTE OF NON-NUTRITIVE SWEETENERS PEPSICO INC (US) 2024-07-24 EP claimed
EP-4294375-A1 METHODS OF LOADING EXTRACELLULAR VESICLES Lonza Sales AG (CH) 2023-12-27 EP claimed
WO-2023227518-A1 POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS DANMARKS TEKNISKE UNIVERSITET (DK) 2023-11-30 WO claimed
EP-4282448-A1 POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS Danmarks Tekniske Universitet (DK) 2023-11-29 EP claimed
US-20220339285-A1 DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE TECHNICAL UNIVERSITY OF DENMARK (DK) 2022-10-27 US claimed
WO-2022178147-A1 METHODS OF LOADING EXTRACELLULAR VESICLES CODIAK BIOSCIENCES, INC. (US) 2022-08-25 WO claimed
EP-3982922-A1 DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE Technical University of Denmark (DK) 2022-04-20 EP claimed
WO-2022044591-A1 CARBONATED BEVERAGE, METHOD FOR PREPARING FLAVOR COMPOSITION, AND METHOD FOR SUPPRESSING BUBBLES OF CARBONATED BEVERAGE 高砂香料工業株式会社 2022-03-03 WO claimed
US-7465696-B2 Lubricating base oil compositions and methods for improving fuel economy in an internal combustion engine using same CHEVRON ORONITE COMPANY, LLC (US) 2008-12-16 US claimed
EP-1688476-A1 Lubricating base oil compositions and methods for improving fuel economy in an internal combustion engine using same Chevron Oronite Company LLC (US) 2006-08-09 EP claimed
US-20060172898-A1 Lubricating base oil compositions and methods for improving fuel economy in an internal combustion engine using same CHEVRON ORONITE COMPANY, LLC 2006-08-03 US claimed
EP-1150722-B1 IMPLANT COMPRISING CALCIUM CEMENT AND HYDROPHOBIC LIQUID ROBERT MATHYS STIFTUNG (CH) 2005-10-05 EP claimed
US-20050037073-A1 Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof ALPHARX INC. (CA) 2005-02-17 US claimed
US-20030072798-A1 Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof ALPHARX INC. (CA) 2003-04-17 US claimed
US-20020102301-A1 Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof ALPHARX INC. (CA) 2002-08-01 US claimed
EP-0508153-A2 Solid ink compositions for thermal ink-jet printing having improved printing characteristics Hewlett-Packard Company (US) 1992-10-14 EP claimed
US-5065167-A Vaporizable solid ink composition for thermal ink-jet printing HEWLETT-PACKARD COMPANY (US) 1991-11-12 US claimed
US-4400295-A REACTION PRODUCT OF A FATTY ACID, AMINO ACID AND A SECONDARY COMPOUND LOIRE COSMETICS CO., LTD. (JP) 1983-08-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220339285-A1 DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE LIPA, LIPE, CEL CA2 648/4885MAPK1 3962/4885GRIK1 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.